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Aim and Objectives. Oral submucous fibrosis (OSF) is a potentially malignant disorder associated with the usage of areca nut. Usage
of processed forms of areca nut is popular among the youth and its carcinogenic effects are not well known. Due to large immigrant
population, various patterns of areca nut usage are seen. The aim of this study is to assess the various quid chewing patterns and
their association with severity of OSF. Materials and Methods. A cross-sectional study was carried out with 250 cases clinically
and histologically diagnosed as having OSF lesion that were selected and subjected to a detailed habit history which was recorded
through preformed questionnaire.The data obtained was statistically analyzed. Results. Among the 250 subjects, males were seen to
be affectedmore than females within the age group of 26–35 years and were having clinical stage I OSF. A combination of processed
areca nut and processed tobacco was used by the majority of the subjects with duration of 1 to 5 years, at a frequency of 3 to 5 quids
per day.Conclusion.The present study confirms the association between oral submucous fibrosis and the quid containing processed
areca nut and processed tobacco and also highlights the increasing youth population using the processed forms of areca nut.
1. Introduction
Habits associated with the oral cavity can have deleterious
effects on the oral health and affect the normal functioning of
the oral cavity. Some habits are developed as a leisure activity
and some are imbibed as a cultural practice. Either way, they
become addictive and can have far reaching effects on oral as
well as general health.
Chewing areca nut has gained popularity due to social
acceptability, religious beliefs, perceived health benefits, and
addiction [1]. Regional variations in the type of areca nut
preparations used and the varied patterns of chewing using
them have led a specific site in the oral cavity to be involved
[2]. The areca nut is either chewed alone or along with betel
leaf and other ingredients such as lime, catechu, spices, or
sweeteners and used either as traditional pan or commercially
used gutkha [3].
Usage of areca nut has been the single-most important
etiological factor considered for development of OSF [4].
The disease is predominantly seen in India, Bangladesh, Sri
Lanka, Pakistan, Taiwan, China, and among other Asians,
with a reported prevalence ranging up to 0.4% in Indian rural
population [2].
Mangalore, which is located at the border of Karnataka
and Kerala, is a predominant areca nut growing region and
has people from both states residing in it as well as a large
number of immigrant population. Therefore, an attempt is
made in this study to assess the various chewing patterns
associated with the severity of oral submucous fibrosis (OSF).
2. Material and Methods
The present cross-sectional study was carried out wherein
250 cases of OSF were selected among the patients attending
our institution and those attending the rural dental camps as
per the clinical criteria and staging set by Haider et al. [5]
(Table 1).
An incisional biopsy was done for histopathological
confirmation after an informed consent was obtained. The
patients were later subjected to a questionnaire regarding the
various patterns of chewing habit and the quid constituents
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Table 1: Haider et al. clinically graded OSF into the following.
Stage I Faucial bands only
Stage II Faucial and buccal bands
Stage III Faucial, buccal, and labial bands
Table 2: Distribution of cases based on the type of quid.
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used. The data obtained from the procedures were tabulated
and statistically analyzed.
3. Results
Thedata collected was analyzed and the results were obtained
and the following observations were made and summarized
in Figures 1–3 and Tables 1–9.
Out of the 250 OSF patients examined, 90.4% were males
(Figure 1) and 31.2% of the cases were in the age of 15–25 years
and 42.4% of the cases were in the age group of 26–35 years
(Figure 2). Among the 250 cases, 52.8% of the cases were of
clinical stage I, 37.6% of the cases were of clinical stage II, and
9.6% of the cases were of clinical stage III (Figure 3).
Among the 250 cases included in the study, 5.6% of the
cases chewed the type II quid, 7.2% of the cases chewed type
III quid, 30.4% of the cases chewed type IV quid, 39.2% of the
cases chewed type V quid, and 17.6% of the cases hadmultiple
quid chewing habits (Table 2).
Among the 14 cases who chewed type II quid, 85.7% of
the cases were having OSF stage I and 14.2% of the cases were
havingOSF stage II. Among the cases whowere chewing type
III quid, 66.6%were havingOSF stage I and 33.3% of the cases
were having OSF stage II. Out of the 76 patients using type IV
quid, 57.8% of the cases were having OSF stage I, 31.5% of the
cases were having OSF stage II, and 10.5% of the cases were
having OSF stage III. Among the 98 cases that were using
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42 (42.85%) 42 (42.85%) 14 (14.28%)
Combined quid
usage (44) 22 (50%) 20 (45.45%) 2 (4.54%)
𝜒
2 = 16.64; 𝑝 = 0.034 SIG.
Table 4: Clinical stage I and frequency.
1-2/day 3–5/day 6–10/day >10/day
Type I 0 0 0 0
Type II 6 (4.5%) 6 (4.5%) 0 0
Type III 4 (3%) 4 (3%) 4 (3%) 0
Type IV 4 (3%) 26 (19.6%) 10 (7.5%) 4 (3%)
Type V 6 (4.5%) 16 (12.12%) 16 (12.12%) 2 (1.5%)
Combined 4 (3%) 16 (12.12%) 2 (1.5%) 0
𝜒
2
= 25.537; 𝑝 = 0.0135 SIG.
Table 5: Clinical stage I and duration.
1–12 months 1–5 years 5–10 years >10 years
Type I 0 0 0 0
Type II 4 (3.0%) 0 2 (1.5%) 6 (4.5%)
Type III 4 (3.0%) 0 2 (1.5%) 6 (4.5%)
Type IV 14 (10.6%) 26 (19.6%) 2 (1.5%) 2 (1.5%)
Type V 10 (7.5%) 24 (18.18%) 8 (6.0%) 0
Combined 2 (1.5%) 12 (9.0%) 4 (3.0%) 4 (3.0%)
𝜒
2
= 53.504; 𝑝 < 0.001 VHS.
type V quid, 42.8% of the cases were having clinical stage
I OSF, 42.8% of the cases were having clinical stage II OSF,
and 14.2% of the cases were having clinical stage III OSF.
In this present study maximum patients were having clinical
stage I OSF and used type V quid and this was found to be
statistically significant (Table 3).
Among the cases seen in clinical stage I, the majority of
the cases chewed 3–5 times daily and were found to use type
IVquid rather than the traditional quid forms.Thiswas found
to be statistically significant (Table 4).
In clinical stage I, the majority of the cases were using
quid for duration of 1–5 years, and the processed forms of quid
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Table 6: Clinical stage II and frequency.
1 to 2/day 3 to 5/day 6–10/day >10/day
Type I 0 0 0 0
Type II 0 0 2 0
Type III 0 2 (2.12%) 2 (2.12%) 2 (2.12%)
Type IV 2 (2.12%) 12 (12.76%) 8 (8.55%) 2 (2.12%)
Type V 2 (2.12%) 18 (19.14%) 12 (12.76%) 8 (8.55%)
Combined 0 8 (8.55%) 6 (6.3%) 6 (6.3%)
𝜒
2
= 12.89; 𝑝 = 0.1675 NS.
Table 7: Clinical stage II and duration.
1–12 months 1–5 years 5–10 years >10 years
Type I 0 0 0 0
Type II 0 2 (2.12%) 0 0
Type III 0 2 (2.12%) 2 (2.12%) 2 (2.12%)
Type IV 2 (2.12%) 22 (23.4%) 0 0
Type V 8 (8.5%) 24 (25.53%) 8 (8.5%) 2 (2.12%)
Combined 0 8 (8.5%) 10 (10.6%) 2 (2.12%)
𝜒
2
= 30.692; 𝑝 < 0.001 VHS.
Table 8: Clinical stage III and frequency.
1 to 2/day 3 to 5/day 6–10/day >10/day
Type I 0 0 0 0
Type II 0 0 0 0
Type III 0 0 0 0
Type IV 0 4 (16.6%) 2 (8.3%) 2 (8.3%)
Type V 0 4 (16.6%) 6 (25.0%) 4 (16.6%)
Combined 0 0 0 2 (8.3%)
𝜒
2
= 5.571; 𝑝 = 0.2335 NS.
Table 9: Clinical stage III and duration.
1–12 months 1–5 year 5–10 year >10 years
Type I 0 0 0 0
Type II 0 0 0 0
Type III 0 0 0 0
Type IV 2 (8.3%) 2 (8.3%) 2 (8.3%) 2 (8.3%)
Type V 0 8 (33.33%) 4 (16.6%) 2 (8.3%)
Combined 0 2 (8.3%) 0 0
𝜒
2
= 1.979; 𝑝 = 0.739 NS.
are seen to be the cause. This association between the type
of quid and duration was found to be very highly significant
(Table 5).
In clinical stage II, themajority of the cases were using the
quid 3–5 times daily, and the cases using the processed forms
have manifested with OSF rather than with the use of the
traditional type III quid.This association between the type of
quid and duration was found to be statistically nonsignificant
(Table 6).
In clinical stage II, themajority of the cases were using the
quid for duration of 1–5 years and the cases showingOSFwere
226 males
24 females









Figure 3: Cases distributed based on clinical staging.
more with the use of the processed quid.This association was
found to be very highly significant (Table 7).
In clinical stage III, all the cases were using processed
forms of areca nut and this association between type of quid
and duration and frequency was found to be nonsignificant
(Tables 8 and 9).
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4. Discussion
The practice of chewing areca nut in a betel quid has a
long history which is deeply ingrained in many sociocultural
and religious activities, especially offered at the social and
wedding gatherings. References to betel nut appear in ancient
Sanskrit literature as early as the 1st century BC.The practice
of chewing betel leaves after meals had become common (75
AD to 300 AD) and Sushruta, a renowned Indian physician,
in his bookMouth andThroatDiseasesmentioned a condition
“Vidari,” that the features of which simulate OSF [3].
Oral submucous fibrosis is an insidious chronic disease
affecting any part of the oral cavity or pharynx, occasionally
proceeded by and/or associated with vesicle formation, and
is always associated with a juxtaepithelial inflammatory
reaction followed by progressive hyalinization of the lamina
propria with epithelial atrophy leading to stiffness of the oral
mucosa and causing trismus and inability to eat [6].
Areca nut, usually incorporated in betel quid, is the fourth
most common psychoactive substance in the world after
caffeine, alcohol, and nicotine and it has been estimated that
betel quid is used by about 10–20% of the world’s population
accounting for up to 600 million areca nut users globally
[7]. There have been numerous studies ascertaining the role
of areca nut in oral cancer and stressing the importance
and methods of screening and early detection of oral cancer
thereby reducing the mortality rate [7–9]. Amalignant trans-
formation rate of 7.6% over a period of 17 years was previously
reported; however, the recent studies indicate the malignant
transformation rate to be 11.7% [8, 10].
The present study was conducted on 250 patients in and
around Mangalore city and showed a male predominance
which could be attributed to the social pattern of the study
area wherein men get access to commercially available prod-
ucts more readily than females.
The 42.4% of cases in the present study were in age group
of 26–35 years and this predominance among the younger
generation could be attributed to wide social acceptability of
areca nut chewing in the form of gutkha as compared to the
traditional betel quid which is considered outdated. Further,
the easy accessibility to the packaged products and the lack of
knowledge about the carcinogenic effects of these products
has led to increased use. Among the cases included in our
study, 5.6% of the cases chewed type II quid, 7.2% of the cases
chewed type III quid, 30.4% of the cases chewed processed
areca nut, 39.2% of the cases chewed processed areca nut
with processed tobacco, and 17.6% of the cases had multiple
quid chewing habits (Figure 3). This was similar to the
observations of Ahmad et al. [11] where around 55% chewed
gutkha only and 16% of fibrosed cases were addicted to pan
chewing habit. Goel et al. [12] in his study reported that 40%
of patients chewed panmasala, 30% chewed betel nut, and the
remaining 30% chewed betel quid.
This study showed an increased prevalence of the use of
type V quid (processed areca nut and processed tobacco),
attributed to the addictive effect associated with the usage of
tobacco. Moreover, the habit is socially acceptable and these
products are easily available which have led to its increased
use.
5. Association between the Type of Quid and
Clinical Staging of OSF
It was seen that, out of the 24 cases which showed clinical
stage III grading, processed form of quid was used when
compared to the cases where traditional forms of quid was
used, which had clinical stage I and clinical stage II of OSF.
This is attributed to the protective effects of the betel leaf
against the harmful alkaloids present in the areca nut. The
betel leaf is rich in beta-carotene and hydroxychavicol which
have the capacity to quench the free radical that is toxic [11].
Another reason for the increased severity and risk of develop-
ingOSF in gutkha chewers is the increased dryweight of areca
nut in gutkha sachets which is approximately 3.26 g, whereas
that in betel quid is 1.14 g [13]. Therefore, the habitual gutkha
users consume more dry weight of tobacco, areca nut, and
slaked lime, which causes nicotine to act synergistically on
the cytotoxicity induced by arecoline (a major areca nut alka-
loid), thereby increasing the vulnerability of buccal mucosal
fibroblasts to damage and enhancing collagen production up
to 170%.There is alsomechanical injury to oral tissues caused
due to the fine grains of areca nut in the gutkha which allow
ground tobacco to adhere to the traumatizedmucosa, leading
to morphologic changes and membrane damage. Thus, areca
nut in combination with tobacco may cause cross-links and
accelerate the onset of OSF in habitual gutkha chewers [14–
16].
6. Association between the Type of
Quid, Frequency, and Duration in
Various Clinical Stages
In the present study, in clinical stage I, around 26 patientswho
chewed type IV quid for a frequency of 3–5/day developed
OSF as compared to only 6 patients who consumed type II
quid (Table 4).
Similarly, in clinical stage I, 26 subjects who chewed type
IV quid for 1–5 years had OSF while those who used type
II and type III quid with the betel leaf did not develop OSF
within 1–5 years (Table 5).
In clinical stage II, around 18 patients who chewed type V
quid for a frequency of 3–5/day had OSF as compared to only
2 who used type II quid (Table 6).
Similarly, 24 subjects who consumed type IV quid for 1–5
years had OSF while only 2 who consumed type II and type
III quid for 1–5 years had OSF (Table 7).
In the above study, association between the clinical
staging and duration was found to be highly significant as
compared to the association between the clinical staging and
frequency of quid usage. The above study also shows that the
subjects who chewed type IV quid developed OSF earlier and
those who chewed type IV quid with a greater frequency
developedmore severe clinical stages ofOSF.This is similar to
the observations done by Pandya et al. where maximum sub-
jects who had histopathological grade III OSF took tobacco
products for 8–10 years or with a frequency of 7–10 times per
day [17]. Kumar et al. also suggested that the patients who
used panmasala with a greater frequency/day developedOSF
with a shorter duration of the habit [18].
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However, the associations of various parameters in clini-
cal stage IIIwere not significant as the patients in clinical stage
III were fewer in number (Tables 8 and 9).
7. Conclusion
Oral submucous fibrosis is a commonly occurring potentially
malignant condition increasingly affecting the youth. The
lack of knowledge of areca nut being a carcinogenic substance
and the easy availability of gutkha and pan masala in social
places have led to increased consumption and spread of this
debilitating disease. The above study highlights the increased
use of processed areca nut among the youth and varied styles
of quid usage in terms of duration and frequency leading to
severity of OSF in Mangalore population. There have been
numerous studies and reviews on the various constituents
of the quid and clinical aspects of OSF and oral cancer in
India.This study serves as an extendedmethodology that can
be used for screening and educating the masses about quid
chewing habits and its association with oral cancer.
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